Fusion Pharma presented an updated data from the ongoing Phase 1/2 study in patients with CML with failure of prior TKI therapy at the 60th Annual Meeting and Exposition (December 1-14, 2018) in San Diego, CA.

Session Name: 632: Chronic Myeloid Leukemia: Therapy: Results of Clinical Trials
Session Date: December 3, 2018
Abstract 790

Download the presentation